 HemOncToday | Everolimus plus paclitaxel failed to improve pathological complete response rate HemOncToday SAN ANTONIO — Adding everolimus to 12 weeks of paclitaxel as neoadjuvant therapy did not improve the rate of pathological complete response in patients with breast cancer who did not respond to treatment with epirubicin/cyclophosphamide with or ... |
